The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies
Background: Due to the lack of comprehensive evidence based on prospective studies, the efficacy and safety of Janus Kinase (JAK) inhibitors (including tofacitinib, ruxolitinib, baricitinib, ritlecitinib and brepocitinib) for alopecia areata (AA) are yet to be proved.Methods: The systematic review a...
Main Authors: | Diqin Yan, Huaying Fan, Min Chen, Lin Xia, Simin Wang, Wenliang Dong, Qian Wang, Suping Niu, Huiying Rao, Liming Chen, Xiaoyan Nie, Yi Fang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-08-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.950450/full |
Similar Items
-
Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
by: Dongfan Wei, et al.
Published: (2023-04-01) -
Transient Efficacy of Tofacitinib in Alopecia Areata Universalis
by: Florian Anzengruber, et al.
Published: (2016-04-01) -
Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib
by: Ji Su Lee, et al.
Published: (2018-11-01) -
Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
by: Alexander Egeberg, et al.
Published: (2023-10-01) -
A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
by: Dillon KAL
Published: (2021-06-01)